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Summary. We studied the effect of monoclonal antibody 
protein dose on the uniformity of radioiodinated antibody 
distribution within tumor masses using quantitative auto- 
radiography. Groups (n = 11-13/group) of athymic nude 
mice with subcutaneous HTB77 human ovarian carcinoma 
xenografls were injected intraperitoneally with an 125I-la- 
beled anticarcinoma-associated antigen mufine mono- 
clonal antibody, 5G6.4, using a high or a low protein dose 
(500 gg or 5 gg). At 6 days post-injection the macroscopic 
and microscopic intratumoral biodistfibution of radio- 
labeled antibody was determined. The degree of hetero- 
geneity of the labeled antibody distribution within each 
tumor was quantified and expressed as the coefficient of  
variation (CV) of the activity levels in serial histological 
sections. Tumors from mice given the 500-gg protein 
doses had substantially lower CV values, 0.327+0.027, 
than did tumors from animals given 5-gg protein doses, 
0.458 + 0.041, (P = 0.0078), indicating that the higher pro- 
tein dose resulted in more homogeneous distribution of 
radioactivity in tumors than did the lower dose. While the 
percentage of the injected dose reaching the tumor was 
comparable between groups, injecting the higher dose of 
protein resulted in significantly lower tumor to non-tumor 
uptake ratios than those obtained for the lower protein 
dose. These data indicate, in this system, that to achieve 
more uniform intratumoral antibody (and radiation for 
radioimmunotherapy) delivery, a relatively high protein 
dose must be administered. However, to obtain this in- 
creased uniformity, a substantial drop in tumor/back- 
ground uptake ratios was seen. Quantitative autoradio- 
graphic evaluation of human tumor xenografts is a useful 
method to assess the intratumoral distribution of anti- 
bodies. 
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Introduction 
Monoclonal antibodies as carriers of radionuclides, drugs, 
and toxins are being intensively investigated for their use 
in both cancer imaging and therapy [27]. Maximal anti- 
body delivery to tumors with minimal uptake in normal 
tissues is desirable for both imaging and therapy. For anti- 
body conjugate therapy, however, the uniformity of anti- 
body distribution within the tumor mass itself is an addi- 
tional concern. A homogeneous intratumoral distribution is 
desirable and probably necessary for many therapeutic ap- 
plications. This is because even though an appropriately 
labeled antibody may be lethal to all cancer cells it binds to, 
if its delivered toxicity is unable to reach all regions within 
a tumor mass, some cells may survive and continue to 
grow. With radioimmunotherapy, the use of higher-energy 
emitters such as 90y may allow for successful tumor 
treatment despite an inhomogeneous distribution because 
the emitted particles travel a substantial distance, but for 
lower-energy ~ and c~ emitters, drugs, and toxins, adequate 
delivery of antibody to most or all cells in a tumor is 
probably obligatory for successful treatment [10]. 
The distribution of monoclonal antibodies within 
tumors may be affected by numerous biological factors that 
influence the accessibility of antibodies to antigenic sites 
(e. g. tumor blood flow, tumor vascularity, vascular perme- 
ability, antibody molecular mass, antigen, antibody affinity 
and tumor interstitial pressure) [8, 12, 13, 15, 18, 22]. It has 
been reported that higher antibody uptake and a more uni- 
form distribution across tumor masses was achieved when 
the tumor was incubated with antibody in vitro than fol- 
lowing systemic administration in vivo. These results indi- 
cate that, in vivo, the antigenic sites are commonly not 
fully saturated [23]. One potential method to improve anti- 
body delivery to the tumor antigenic sites is to administer 
higher levels of antibody protein so that antibody might 
diffuse more deeply into tumors. Some reports indicate that 
antibody protein dose does not have a significant effect 
upon the percentage of the injected dose of iodinated anti- 
body reaching either the tumor xenografts or normal tis- 
sues in cancer models [24, 30]. However, when an lnIn- 
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labeled anti-carcinoembryonic (CEA) antigen monoclonal 
antibody is used in patients, an increase in the accumula- 
tion of activity in the tumor relative to the background 
levels has been seen when the protein dose was increased 
[20]. Others have shown, in an animal model of colon 
cancer, that an anti-(colorectal cancer) monoclonal anti- 
body, given at high protein doses, targets less well than at 
a lower protein dose, probably because of antibody satura- 
tion of tumor antigenic sites [6]. Thus, some variability of 
the effect of protein is present, depending on the system 
studied. 
The effects of the protein dose on the distribution of 
radioantibody within the tumor itself have not been pre- 
viously studied quantitatively. Initial qualitative autoradio- 
graphic techniques have, however, detected concentrations 
of radioantibodies primarily in perivascular areas in tumors 
following intravenous antibody delivery, probably because 
of the binding of high-affinity antibody [5]. Recently, qual- 
itative ilmnunohistochemical studies have demonstrated 
that a more uniform intratumoral distribution of antibody 
has been achieved with a higher administered antibody 
protein dose in animal studies [ 19]. In addition, using qual- 
itative autoradiographic techniques, Blumenthal et al. were 
able to demonstrate that, for two specific antibodies to 
CEA that demonstrated good targeting, the intratumoral 
antibody distribution following i.v. administration ap- 
peared to be more uniform at high, rather than low, protein 
doses in a colon cancer xenograft system. 
We evaluated the effect of antibody protein dose on the 
delivery and distribution of radioactivity within ovarian 
adenocarcinoma masses, studied with a radioiodinated an- 
ticarcinoma monoclonal antibody, 5G6.4 [31], injected 
into nude mice bearing subcutaneous human ovarian carci- 
noma xenografts. Whole-body and intratumoral distribu- 
tions of the labeled antibody were digitally quantified us- 
ing a computer image-analysis system. This quantitative 
method was developed to provide an objective means for 
comparing the antoradiographs obtained from the different 
tumors [35]. Our initial results with this method were re- 
cently reported in abstract form [34]. 
Materials and methods 
Monoclonal antibody. 5G6.4 is an IgG2ak murine monoclonal antibody 
reactive with epithelial carcinomas [31]. It was produced in mouse 
ascites and purified by staphylococcal protein A column chromatogra- 
phy, eluting at pH 5. Protein concentration was determined by the color- 
imetric method developed by Bradford using bovine IgG (Bio-Rad) as 
reference standard [3]. The purity of the 5G6.4 preparation was verified 
by sodium doclecyl snifate/polyacrylamide gel electrophoresis under 
reducing conditions. 
Antibody radiolabeling. The iodogen method was used to label the anti- 
body with sodium [125I]iodide (ICN) [7]. The radiolabeling reaction 
consisted of 2.69 mCi 125I reacted with a protein mass of 94.5 gg at a 
concentration of 10.5 mg/ml. The preparation was purified via anion-ex- 
change chromatography (Bio-Rad AG l-X8, 200-400 mesh). Free- 
iodine contamination was determined by silica gel TLC; only 2% free 
iodine was measured in the final preparation used for this study. Im- 
munoreactivity was confirmed by a direct cell binding assay, which was 
performed with viable human ovarian carcinoma (HTB77 IP3) target 
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Fig. 1. Two hypothetical nine-pixel tumor sections treated with one dose 
or with two doses. The numbers in the squares represent the activities 
(gCi/g) for each pixel of these sections. The distributions are identical, 
but the means_+SD of the uptakes are different. The coefficient of 
variation, calculated by dividing the standard deviation by the mean, is 
identical between the two "tumors" and is used as a measure of the 
uniformity of distribution for the different uptakes 
cells under conditions of antigen excess [33]. I25I-labeled 5G6.4 demon- 
strated a baseline immunoreactivity of 65.1 4-2.3 %. 
Animal model. Female nude mice (nu/nu) (Swiss) were injected subcu- 
taneously with a single-cell suspension of 10 x 106 HTB77 IP3 human 
ovarian carcinoma cells. When the tumors reached at least 5 mm in 
diameter, the biodistribution studies were performed. 
Biodistribution study. Intraperitoneal injections of the 125I-5G6.4 were 
administered, taking advantage of egress of the antibody from the perito- 
neal cavity to the systemic circulation [32]. An initial pilot study with 
three groups of mice receiving dosages of 5, 50, or 500 gg 5G6.4 was 
performed to test the feasibility of the method. Subsequently, in the 
definitive study, the mice were divided into two groups: both groups 
received approximately 75 gCi 125I-5G6.4 each but at different protein 
doses: 5 gg (n = 11) and 500 btg (n = 13). To prepare the 500-gg doses, 
5 gg radiolabeled antibody was mixed with 495 gg unlabeled 5G6.4 
antibody prior to injection. All mice were sacrificed 6 days after injection 
and tissues were weighed and counted in a gamma counter. The percent- 
age of the injected dose per gram was calculated using standard tech- 
niques [28, 29, 32]. 
Quantitative autoradiography. Excised tumors were quickly frozen at 
-70 °C. Representative frozen sections of each tumor, primarily from 
equatorial regions, were cut at 12-gm thickness at a minimum distance of 
600 gm from one another. Contact autoradiography was performed by 
exposing Kodak Xar5 film to the sections for 64 h at room temperature 
[14]. Standards correlating activity in gCi/g with film absorbance were 
obtained from autoradiographs of frozen sections of the livers of two 
BALB/e mice injected with 100 ~tCi and 200 gCi of the same 125I-5G6.4 
preparation used in the biodistribution study. Livers were weighed, 
counted, frozen, and sectioned at 12 gin. A timed course of exposure 
(between 2 h and 128 h) was used to obtain a standard gray scale correlat- 










developed by a commercial Du Pont developer. Representative sections 
from each tumor were stained with hematoxylin and eosin to assess the 
tumor architecture and degree of necrosis. 
The autoradiographs of each section (mean of 11) of tumor were 
analyzed at the Image Analysis Facility at the University of Michigan 
u C i t ~  
Fig. 2 A, B. Examples of the quantitative auto- 
radiographic analysis used in this study. A A rep- 
resentative section from a tumor removed from a 
mouse that received 500 gg 125I-5G6.4. The 
coefficient of variation for this section was 0.347. 
B A section from a tumor removed from a mouse 
that received 5 gg 125I-5G6.4. The coefficient of 
variation for this section was 0.504. a, The sec- 
tion stained with hematoxylin and eosin; b, the 
autoradiograph of the same section; c, the image 
generated from the video densitometer computer 
system; d, the plot of the number of pixels in the 
tumor at each activity level detected by the densi- 
tometer 
Medical Center. Relative absorbance was measured by an International 
Imaging System model 75 image processor using a Dage-MTI Newvicon 
camera with a 25-mm 1 : 1.4 Vidicon lens. The system is connected to a 
Masscomp 500 dual processor 68 000 based computer, which runs a 
real-time version of the Unix operating system. Images were digitized 
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into a 512 x 512 array of pixels (point measurements) with 256 absor- 
bance levels. The width of each pixel square was 155 ~tm. Prior to 
analysis the system was normalized to ensure that each pixel had a linear 
intensity/absorbance response. This was done by taking a series of im- 
ages from the brightest background field that the camera analyzed (in this 
case a blank piece of film) to the darkest (a black field). A computer 
program then corrected every pixel for a linear response. Each absor- 
bance level was then automatically converted to a specific activity level 
(gCi/g) by comparison to the standard gray scale. 
This process enabled us to assign specific radioactivity levels to 
every pixel in the autoradiographic images. The outline of each auto- 
radiographic image was carefully traced so that only regions correlating 
to tumor were analyzed. Plots of activity level (gCi/g) versus area of the 
cross-section (pixels) were generated for each tumor. The heterogeneity 
of intratumoral distribution is expressed by the standard deviation from 
the mean activity level. In order to compare different tumors, the coeffi- 
cient of variation (CV) of tumor uptake of radioactivity was calculated 
for each of them. Tumors with identical antibody distribution patterns but 
different overall uptakes will exhibit different mean antibody uptake 
percentages and differ in their standard deviations. The coefficient of 
variation, which is obtained by dividing the standard deviation by the 
mean tumor uptake of radioactivity for these tumors is, however, identi- 
cal (0.408) (Fig. 1). Such a measure allows one to compare the uniform- 
ity of radioantibody uptake between different tumors, even if the absolute 
tumor uptake is substantially different. A low CV indicates less variation 
in activity of different regions in a tumor and therefore a more homoge- 
neous intratumoral distribution. An average CV was obtained from the 
multiple sections obtained from each tumor in each group. The difference 
between the two groups was analyzed by an unpaired, one-tail t-test. 
Immunohistochemistry. Two to three representative sections of each 
autoradiographed tumor were stained with hematoxylin and eosin to 
assess architecture and extent of necrosis. Additional HTB77 IP3 tumors 
were grown for immunohistochemical study in four nude mice, which 
were not injected in vivo with radiolabeled monoclonal antibodies. The 
tumors were removed and frozen in isopentane cooled by liquid nitrogen. 
Cross-sections, 10 ~tm thick, from the middle of the tumors were cut in 
the cryostat at -20 ° C and mounted on poly-L-lysine-coated slides. The 
sections were air dried and kept at -70 ° C until stained. 
Thawed sections were fixed for 10 min in buffered formalin (4% in 
phosphate-buffered saline, PBS, pH 7.0) and were stained using a modi- 
fication of the indirect immunoperoxidase method of Hsu [ 11]: sections 
were incubated with a 10 gg/ml solution of biotinylated 5G6.4 (ETAC 
method) [4] in diluent (4% bovine serum albumin, 1% horse serum in 
PBS) for 30 rain, washed with PBS and then further incubated with 
avidin-peroxidase conjugate for 30 min (Vectastain Kit, Vector). The 
sections were then washed with PBS and the bound antibody was visual- 
ized with diaminobenzidine and counterstained with hematoxylin. Sec- 
tions incubated with the diluent alone were used as controls. 
Results 
On microscopic examination, the tumors were glandular  
(Fig. 2A,  B) and did not contain large areas of necrosis; 
however,  scattered small  necrotic foci could be seen 
throughout the entire tumor. All  tumors that were immu-  
nostained expressed b inding sites for this antibody. Of the 
tumor cells in the sections, 7 0 % - 9 0 %  reacted with the 
5G6.4 antibody (Fig. 3 A, B). Stained granules were seen 
throughout the cytoplasm of most  of the cells. In some 
cells, concentrat ions of stained granules were observed 
along the cell membranes  (Fig. 4A,  B). No staining was 
seen in the control sections (Figs. 3, 4) or in the connective 
tissue of the positive sections (Fig. 4). 
The in vivo intratumoral  distribution of the labeled anti- 
body, evaluated by quantitative autoradiography, was 
Fig. 3 A, B. Micrographs of histological sections of human ovarian carci- 
noma tumor xenograft grown in the nude mouse. (200 x ). A Section 
incubated with biotinylated 5G6.4 monoclonal antibody. Most of the 
cells are 5G6.4-positive (the antigen is reasonably uniform in its distribu- 
tion). Some cells (arrowheads) and the:connective tissue (arrow) are 
5G6.4-negative. The lumens do not contain 5G6.4-positive material. The 
scale indicates 155 gm, which is the length of the side of a pixel. B Sec- 
tion incubated with diluent (control). No staining is seen 
moderately heterogeneous. Examples of the results of the 
quantitative autoradiographic analysis for the two doses 
are presented in Fig. 2A,  B. The number  of animals em- 
ployed in the initial  pilot study with 5 - ,  50- and 500-gg 
dose groups (n = 4, 5) was too small to achieve statistical 
significance; however,  the results from this feasibility 
study did suggest that the CV of the activity levels obtained 
in autoradiographs from tumors treated with 500 gg 
(0.289 + 0.06 SEM) was much smaller than in either the 
5- or 50-gg groups. The differences between the CV of the 
5- and 50-gg groups, although not necessarily unworthy of 
future investigation, were not felt to be significant 
(0.401___0.04 and 0 . 5 0 1 + 0 . 0 5  respectively), especially 
considering the variabili ty within each group. Therefore, in 
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Table 1. The CV of the in vivo intratumoral distribution of 125I-5G6.4 
activity a 
CV for protein dose of 














0.458 _+ .044 0.327 _+ .027 
mean + SEM mean_+ SEM 
The values were obtained from serial sections from each tumor 
a Coefficient of variation of individual tumors. CV at both protein dose 
levels demonstrate some overlap, yet as a group, significantly lower 
values were seen at the higher protein dose. The lower CV indicates more 
homogeneous antibody distribution at the high protein dose 
Fig. 4A, B. Micrographs of tumor cells from xenograft stained with 
5G6.4. (1250 × ) A Stained granules are seen in the cytoplasm and are 
concentrated along the membranes of the cells. B Cells in a control 
section. No staining is seen 
the definitive study we expanded the number of animals in 
the 5-gg and 500-gg groups to 11-13/group for further 
evaluation. The uniformity of radioantibody distribution in 
the 500-gg protein dose group was substantially greater 
than in the 5-btg protein dose group at the 6-day time point 
after injection. This relatively long time after injection was 
chosen, as at this time tumor-specific binding predomi- 
nates [32]. The mean CV of the activity levels of the 
autoradiographs from the 500-gg group was 0.327 _+ 0.027 
and that of the 5-gg group was 0.458 _+ 0.044 (P = 0.0078) 
(P <0.01) (Table 1). These results provide strong support 
for our hypothesis that a more uniform intratumoral distri- 
bution of antibody is achieved when higher protein doses 
are administered. 
Changing the protein dose from 5 gg to 500 gg did not 
significantly affect the fraction of the injected dose reach- 
ing the tumor. However, increased amounts of radioactivi- 
ty were found in the normal tissues at the higher doses, 
probably because of higher blood levels (Table 2). As a 
result, tumor to normal tissue ratios of delivered radioac- 
tivity were significantly lower at the 500-gg level than at 
the 5-gg level (P <0.05). Tumor size was not found to be a 
factor affecting the intratumoral distribution in this study, 
there being no correlation between the CV values of the 
intratumoral radioactivity and the tumor weights. The 
mean tumor weights were comparable between the groups: 
5 gg, 0.971 +0.206 g; 500 gg, 0.885 _+0.199 g. 
Discussion 
Our study quantitatively determined the effect of antibody 
protein dose on overall and intratumoral distribution of 
125I-5G6.4 monoclonal antibody in nude mice with human 
ovarian carcinoma xenografts 6 days after injection. Our 
study differs from prior theoretical and qualitative studies 
in that we applied this quantitative imaging method to 
assess this question objectively [2, 8, 19] in large groups of 
animals with multiple sequential sections from each tumor, 
so that over 240 different tumor sections were quantita- 
tively assessed. With this quantitative method, we have 
been able to demonstrate that increasing the protein dose 
from 5 gg to 500 gg in this system significantly increases 
the uniformity of intratumoral distribution of antibody. The 
quantitative approach removes any potential subconscious 
or conscious observer bias in the interpretation of qualita- 
tive studies. Our study further demonstrates that this in- 
creased uniformity comes with a price of a decrease in 
target to background ratios. 
Our quantitative results are somewhat similar to those 
recently reported by Blumenthal and colleagues, in which 
two different monoclonal antibodies reactive with car- 
cinoembryonic antigen were qualitatively shown to have a 
more uniform intratumoral distribution when a high pro- 
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Table 2. Biodistribution of 125I-5G6.4 
12SI-distribution (%)" 
Group Liver Kidney Spleen Lung Muscle Small intest. Ovary Blood Tumor 
5gg(n=  11) 0.681+0.107 0.926+0.184 0.763+0.142 2.278+0.417 0.256_+0.037 0.655_+0.131 1.168_+0.198 3.893+0.726 3.487_+0.474 
500gg (n = 11) 1.191_+0.100 1.680_+0.145 1.388_+0.154 3.350_+0.471 0.440_+0.033 1.184+0.15 2.027_+0.179 6.120+0.655 3.269_+0.473 
t-test (P) 0.0014 0.002 0.0048 0.075 0.0001 0.0153 0.0029 0.0183 0.4353 
a The table shows the mean percentage injected dose per gram tissue _+ 
standard error of mean (SEM), of radioantibody reaching normal tissue 
and tumor in each group and reveals higher uptake of radiolabeled 
antibody, 5G6.4, at the 500-gg injected protein dose in the normal tissues 
at sacrifice. No significant difference was found between the two groups 
in the amount  of dose reaching the subcutaneous tumor xenografts 
tein dose rather than a low dose was used [2]. These inves- 
tigators, however, were unable to demonstrate improved 
intratumoral uniformity of uptake with higher protein 
doses of a nonspecific antibody where uniform uptake was 
seen, even with a low protein dose and for a specific 
antibody that targeted tumor less well than with their best 
reagents. The improved homogeneity in intratumoral up- 
take of radioantibody we demonstrated, even with rela- 
tively low target to background ratios, indicates that pro- 
tein dose may have a substantial effect on targeting at the 
microscopic level, even in systems where antibody target- 
ing is not optimal. 
It is likely that the lower tumor to normal organ ratios 
seen in our animals at high protein doses were due to 
partial or complete accessible tumor antigenic saturation at 
the 500-gg dose. Of note, however, is that our percentage 
injected dose per gram in the tumor did not actually fall at 
higher protein doses, rather the percentage uptake in nor- 
mal tissues increased. It is thus possible that a component 
of the decrement in target to background ratios at the high 
protein dose was due to higher blood levels of radioactivity 
in the high-protein dose group because of the genetic back- 
ground of the nude mice (Swiss) that were used and the 
IgG2a isotype of the 5G6.4 antibody. 
Rapid blood clearance of IgG2a monoclonal antibodies 
when low protein doses (<100 gg) are given to nude mice 
has been reported [25]. This is probably because mouse 
IgG2a are selectively cleared by the liver and spleen in 
these animals. Higher protein doses (>100 gg) were re- 
ported to block the rapid clearance of IgG2a and result in 
higher blood radioantibody levels [25]. Higher blood 
radioantibody levels logically can result in higher delivery 
of antibody to normal tissues. We did not observe (at the 
6-day time point we examined), an increase in splenic or 
hepatic radioactivity in the low protein dose group com- 
pared to the higher protein dose group. Six days post-injec- 
tion may not be the optimal time to detect increased 125I 
uptake in the liver and spleen, however. At this late time, 
dehalogenation of antibody may have occurred, particu- 
larly in the liver, which could mask increased targeting to 
these structures. 
It is possible that antibody cross-reactivity with low 
levels of circulating antigen and attendant rapid clearance 
of antibody antigen complexes could have occurred at our 
lower protein doses, which were largely blocked at the high 
protein dose. We have, however, not been able to demon- 
strate circulating antigen in this system (Wahl et al. unpub- 
lished data) and we do not believe this latter suggestion 
explains our findings. 
Our in vivo data, showing improved homogeneity of 
tumor uptake, are parallel to in vivo results and also similar 
to in vitro data reported by Kwok, who used multicellular 
spheroids and showed that tumor antigenic sites were sat- 
urable [2, 17]. It has, however, been somewhat difficult to 
demonstrate tumor saturation in vivo. Indeed, prior studies 
by ourselves in another antibody/tumor system showed no 
clear change in the percentage injected dose per gram of 
iodinated intact antibody reaching tumors in a melanoma 
xenograft system at protein doses ranging from 6.25 gg to 
1.875 mg 125I-labeled 225.285 or 763.24 T monoclonal 
anti-melanoma monoclonal antibodies [30]. 
Increasing the antibody protein dose from 0.001 mg to 
1.0 mg did not improve tumor to normal tissue ratios nor 
improve external scintigraphic contrast of human colonic 
cancer xenografts on hamsters [24]. More recent studies, 
however, were performed in a nude mouse where the ani- 
mal weight was substantially lower and tumor saturation 
could, and was, more easily accomplished [2]. Only 
slightly increased levels of 13q-labeled antibody reached 
murine lymphomas at progressively higher protein doses 
[1]. A decline in fractional anti-(colorectal cancer) mono- 
clonal antibody uptake to colon cancer xenografts in ham- 
sters at protein doses above 100 p.g was seen in another 
study, but full tumor saturation was not achieved at this 
dose [6]. 
These data indicate that, in selected animal models, 
some element of tumor saturation is possible with high 
doses of antibody protein, though very high protein levels 
are generally required. Thus, our quantitative experimental 
results partially support antibody localization models and 
concepts previously outlined by several groups [2, 8, 9, 12, 
13, 17, 19, 26]. These concepts suggest that higher protein 
doses should improve the uniformity of antibody distribu- 
tion in tumors and result in increased penetration of anti- 
body away from blood vessels into tumors. We did not, 
however, observe substantial difficulty in permeating the 
central portions of our tumor xenografts with antibody. 
Certainly, additional studies with antibody fragments and 
at other time points would be useful to address whether 
better penetration is possible, as has been suggested in 
theoretical and initial qualitative autoradiographic studies 
[8,211. 
The implications of uniform distribution of radioactivi- 
ty within a tumor are somewhat dependent on the choice of 
radionuclide for tumor therapy [10, 16]. If a low protein 
dose of antibody is used, it would appear from our study 
and others that much of the antibody molecule will bind to 
tumor-associated antigen located near the vessels that enter 
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the tumor.  W i t h  higher  prote in  doses,  greater  d i f fus ion 
seems to be  achievable .  This lat ter  more  homogeneous  
dis t r ibut ion would  p robab ly  be  necessary  for t rea tment  
with low-energy  [~ par t ic les  or o~ part ic les ,  or drug-ant i -  
body  conjugates ,  to be  successful .  For  therapy with more  
energet ic  ~ emitters,  such as y t ter ium-90,  a less un i fo rm 
dis t r ibut ion of  rad iopharmaceu t ica l s  in tumors  may  be ac- 
ceptable  [10, 16]. For  tumor  imaging,  h igh- leve l  local iza-  
t ion of  an t ibody to the tumor  would  be  necessary ,  whi le  
un i fo rm dis t r ibut ion o f  rad ioac t iv i ty  wi th in  the tumor  
would  be  less essential .  Thus,  lower  prote in  doses may  be  
per fec t ly  appropr ia te  for tumor  imaging  and m a y  offer 
advantages  over  h igher  prote in  doses.  
The  prec ise  degree  of  homogeneous  in t ra tumoral  radio-  
act ivi ty  dis t r ibut ion of  an t ibody conjugates  required for 
therapeut ic  ef f icacy remains  to be determined.  Quant i ta t ive  
au toradiographic  studies such as ours may  be  helpful  in 
address ing this issue. 
I n  s u m m a r y  
Our study demonst ra tes  that, in a human  ovar ian  carcino-  
m a  xenograf t  sys tem in nude  mice,  a re la t ive ly  low prote in  
dose  (5 gg)  o f  rad io labe led  ant ibody results in s ignif icant ly  
super ior  target ing compared  to a higher  (500 gg)  prote in  
dose.  The  higher  pro te in  dose,  however ,  results  in a signif-  
icant ly  more  un i fo rm dis t r ibut ion of  rad ioac t iv i ty  wi th in  
the tumor  than the lower  dose.  Thus, an opt imal  prote in  
dose,  at least  in this an imal  system, m a y  exis t  for  therapy 
whi le  another  op t imal  prote in  dose may  exist  for  imaging.  
Addi t iona l  quant i ta t ive studies in other  an imal  mode l s  and 
patients ,  which  address  this issue, wil l  be o f  interest.  
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